Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
Cristina Menni,Kerstin Klaser,Anna C May,Lorenzo Polidori,Joan Capdevila,Panayiotis Louca,Carole H. Sudre,Long H. Nguyen,David A. Drew,Jordi Merino,Christina Hu,Somesh Selvachandran,Michela Antonelli,Benjamin S Murray,Liane S Canas,Erika Molteni,Mark S. Graham,Marc Modat,Amit Joshi,Massimo Mangino,Alexander Hammers,Anna Goodman,Andrew T. Chan,Jonathan Wolf,Claire J. Steves,Ana M. Valdes,Sebastien Ourselin,Tim D. Spector +27 more
TLDR
In this article, the authors examined the proportion and probability of self-reported systemic and local side-effects within 8 days of vaccination in individuals using the COVID Symptom Study app who received one or two doses of the BNT162b2 vaccine or one dose of the ChAdOx1 nCoV-19 vaccine.Abstract:
Summary Background The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We aimed to investigate the safety and effectiveness of these vaccines in a UK community setting. Methods In this prospective observational study, we examined the proportion and probability of self-reported systemic and local side-effects within 8 days of vaccination in individuals using the COVID Symptom Study app who received one or two doses of the BNT162b2 vaccine or one dose of the ChAdOx1 nCoV-19 vaccine. We also compared infection rates in a subset of vaccinated individuals subsequently tested for SARS-CoV-2 with PCR or lateral flow tests with infection rates in unvaccinated controls. All analyses were adjusted by age (≤55 years vs >55 years), sex, health-care worker status (binary variable), obesity (BMI Findings Between Dec 8, and March 10, 2021, 627 383 individuals reported being vaccinated with 655 590 doses: 282 103 received one dose of BNT162b2, of whom 28 207 received a second dose, and 345 280 received one dose of ChAdOx1 nCoV-19. Systemic side-effects were reported by 13·5% (38 155 of 282 103) of individuals after the first dose of BNT162b2, by 22·0% (6216 of 28 207) after the second dose of BNT162b2, and by 33·7% (116 473 of 345 280) after the first dose of ChAdOx1 nCoV-19. Local side-effects were reported by 71·9% (150 023 of 208 767) of individuals after the first dose of BNT162b2, by 68·5% (9025 of 13 179) after the second dose of BNT162b2, and by 58·7% (104 282 of 177 655) after the first dose of ChAdOx1 nCoV-19. Systemic side-effects were more common (1·6 times after the first dose of ChAdOx1 nCoV-19 and 2·9 times after the first dose of BNT162b2) among individuals with previous SARS-CoV-2 infection than among those without known past infection. Local effects were similarly higher in individuals previously infected than in those without known past infection (1·4 times after the first dose of ChAdOx1 nCoV-19 and 1·2 times after the first dose of BNT162b2). 3106 of 103 622 vaccinated individuals and 50 340 of 464 356 unvaccinated controls tested positive for SARS-CoV-2 infection. Significant reductions in infection risk were seen starting at 12 days after the first dose, reaching 60% (95% CI 49–68) for ChAdOx1 nCoV-19 and 69% (66–72) for BNT162b2 at 21–44 days and 72% (63–79) for BNT162b2 after 45–59 days. Interpretation Systemic and local side-effects after BNT162b2 and ChAdOx1 nCoV-19 vaccination occur at frequencies lower than reported in phase 3 trials. Both vaccines decrease the risk of SARS-CoV-2 infection after 12 days. Funding ZOE Global, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, UK Medical Research Council, Wellcome Trust, UK Research and Innovation, American Gastroenterological Association.read more
Citations
More filters
Journal ArticleDOI
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Noam Barda,Noa Dagan,Yatir Ben-Shlomo,Eldad Kepten,Jacob Waxman,Reut Ohana,Miguel A. Hernán,Marc Lipsitch,Isaac S. Kohane,Doron Netzer,Ben Y. Reis,Ran D. Balicer +11 more
TL;DR: In this paper, the authors showed that messenger RNA (mRNA)-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these tria...
Journal ArticleDOI
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study
TL;DR: In this paper , the authors identify risk factors for post-vaccination SARS-CoV-2 infection and describe the characteristics of post vaccination illness. But some people still become infected with SARS after vaccination, and almost all symptoms were reported less frequently in infected vaccinated individuals than in infected unvaccinated individuals.
Journal ArticleDOI
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Michela Antonelli,Rose S. Penfold,Jordi Merino,Carole H. Sudre,Erika Molteni,Sarah Berry,Liane S Canas,Mark S. Graham,Kerstin Klaser,Marc Modat,Benjamin J. Murray,Eric Kerfoot,Liyuan Chen,Jie Deng,Marc F Österdahl,Marc F Österdahl,Nathan J. Cheetham,David A. Drew,Long H. Nguyen,Joan Capdevila Pujol,Christina Hu,Somesh Selvachandran,Lorenzo Polidori,Anna May,Jonathan Wolf,Andrew T. Chan,Alexander Hammers,Emma L. Duncan,Tim D. Spector,Sebastien Ourselin,Claire J. Steves,Claire J. Steves +31 more
TL;DR: In this article, the authors identify risk factors for post-vaccination SARS-CoV-2 infection and describe the characteristics of post-vaccination illness, using self-reported data from UK-based, adult users of the COVID Symptom Study mobile phone app, including demographics, geographical location, health risk factors, and COVID-19 test results, symptoms, and vaccinations.
Journal ArticleDOI
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
Martina Patone,Lahiru Handunnetthi,Defne Saatci,Jiafeng Pan,Srinivasa Vittal Katikireddi,Saif Razvi,David M. Hunt,Xue W Mei,Sharon Dixon,Francesco Zaccardi,Kamlesh Khunti,Peter J. Watkinson,Carol Coupland,Carol Coupland,James Doidge,David A Harrison,Rommel Ravanan,Aziz Sheikh,Aziz Sheikh,Chris Robertson,Julia Hippisley-Cox +20 more
TL;DR: In this article, a self-controlled case series study was conducted to investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 (n= 12,134,782), and after a SARS-coV-2-positive test.
Journal ArticleDOI
Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
Daniel Ayoubkhani,Charlotte R Bermingham,Koen B. Pouwels,Myer Glickman,Vahé Nafilyan,Francesco Zaccardi,Kamlesh Khunti,Nisreen A Alwan,A. Walker +8 more
TL;DR: The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days, although longer follow- up is needed.
References
More filters
Posted ContentDOI
Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine
TL;DR: In this paper, the authors show that the antibody response to the first vaccine dose in individuals with pre-existing immunity is equal to or even exceeds the titers found in naive individuals after the second dose, and that the reactogenicity is significantly higher in individuals who have been infected with SARS-CoV-2 in the past.
Posted ContentDOI
The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence
TL;DR: In this paper, the authors evaluated the short-term effectiveness of the first dose of the BNT162b2-vaccine against SARS-CoV-2 infection.
Posted ContentDOI
Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million patients using OpenSAFELY
Helen J Curtis,Peter Inglesby,Caroline E Morton,Brian MacKenna,Alex J Walker,Jessica Morley,Amir Mehrkar,Seb Bacon,George Hickman,Chris Bates,Richard Croker,David M. Evans,Tom Ward,Jonathan Cockburn,Simon Davy,Krishnan Bhaskaran,Anna Schultze,Christopher T Rentsch,Elizabeth A. Williamson,William J Hulme,Amelia Green,Anna Rowan,Louis Fisher,Helen Mcdonald,Laurie A. Tomlinson,Rohini Mathur,Henry Drysdale,Rosalind M Eggo,Kevin Wing,Wong Ay,Harriet Forbes,John Parry,Frank Hester,Sam Harper,Shaun O'Hanlon,Alex Eavis,Richard Jarvis,Dima Avramov,Paul D. Griffiths,Aaron Fowles,Nasreen Parkes,Ian J. Douglas,S J W Evans,Liam Smeeth,Ben Goldacre +44 more
TL;DR: In this article, the authors developed algorithms to identify key demographic and clinical subgroups within this population and generated descriptive statistics on proportion of eligible patients receiving the vaccine among key Joint Committee on Vaccination and Immunisation (JCVI) target groups.
Posted ContentDOI
Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of 'real-world' vaccination outcomes from Israel.
Paul R. Hunter,Julii Brainard +1 more
TL;DR: In this article, the authors used a pooled estimate of the daily incidence rate during days 1 to 12 as the counterfactual estimate of incidence without disease and estimated confidence intervals using Monte Carlo modelling.
Journal ArticleDOI
Detecting COVID-19 infection hotspots in England using large-scale self-reported data from a mobile application: a prospective, observational study.
Thomas Varsavsky,Mark S. Graham,Liane S Canas,Sajaysurya Ganesh,Joan Capedevilla Pujol,Carole H. Sudre,Carole H. Sudre,Benjamin J. Murray,Marc Modat,M. Jorge Cardoso,Christina M Astley,David A. Drew,Long H. Nguyen,Tove Fall,Maria F. Gomez,Paul W. Franks,Andrew T. Chan,Richard Davies,Jonathan Wolf,Claire J. Steves,Tim D. Spector,Sebastien Ourselin +21 more
TL;DR: Estimates of incidence and prevalence of COVID-19 showed a similar sensitivity to changes to those reported in the ONS and REACT-1 studies, and geographically granular estimates were used to highlight regions with rapidly increasing case numbers, or hotspots.
Related Papers (5)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
P M Folegatti,Katie J. Ewer,Parvinder K. Aley,Brian Angus,Stephan Becker,Sandra Belij-Rammerstorfer,D Bellamy,S Bibi,M Bittaye,Elizabeth A. Clutterbuck,Christina Dold,Saul N. Faust,Adam Finn,Amy Flaxman,Bassam Hallis,Paul T. Heath,D Jenkin,Rajeka Lazarus,R Makinson,Angela M. Minassian,Katrina M Pollock,M N Ramasamy,Hannah Robinson,Matthew D. Snape,R Tarrant,Merryn Voysey,Catherine M. Green,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +31 more